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Abstract 
A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA‑ARIA 
Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good 
Practice focusing on the implementation of multi‑sectoral care pathways using emerging technologies with real life 
data in rhinitis and asthma multi‑morbidity. The European Union Joint Action on Chronic Diseases and Promoting 
Healthy Ageing across the Life Cycle (JA‑CHRODIS) has developed a checklist of 28 items for the evaluation of Good 
Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community 
dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of 
JA‑CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 
12 countries, assessed the 28 items using a Survey Monkey‑based questionnaire. A visual analogue scale (VAS) from 0 
(strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). 
MASK is following the JA‑CHRODIS recommendations for the evaluation of Good Practices.
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Background
European Innovation Partnerships (EIPs) aim to enhance 
European Union (EU) competitiveness and tackle societal 
challenges through research and innovation. To tackle 
the potential of ageing in the EU, the European Commis-
sion-within its Innovation Union policy-launched the 
European Innovation Partnership on Active and Healthy 
Ageing, Directorate General for Health and Food Safety, 
Directorate General for Communications Networks, 
Content & Technology (EIP on AHA, DG Santé and DG 
CONNECT) [1]. The B3 Action Plan promotes integrated 
care models for chronic diseases, including the use of 
remote monitoring.
The initiative AIRWAYS ICPs (EIP on AHA) is the 
model of chronic diseases of the B3 Action Plan [2, 3]. 
It is a GARD (Global Alliance against Chronic Respira-
tory Diseases, WHO) Research Demonstration Project 
[4]. AIRWAYS ICPs was initiated in 2013 by the EIP on 
AHA Reference Site MACVIA-LR (Contre les MAladies 
Chroniques pour un VIeillissement Actif en Languedoc-
Roussillon, France) [5]. The aim of AIRWAYS ICPs was 
to launch a collaboration to develop practical multi-sec-
toral care pathways (ICPs) in order to: (1) reduce chronic 
respiratory disease burden, mortality and multi-morbid-
ity; (2) improve education of all stakeholders; (3) improve 
work productivity; (4) promote AHA; and (5) reduce 
inequities in all populations globally [3].
The initiative Allergic Rhinitis and its Impact on 
Asthma (ARIA) commenced during a World Health 
Organization (WHO) workshop in 1999 [6]. It was devel-
oped as a guideline [7] using the Grading of Recom-
mendations Assessment, Development and Evaluation 
(GRADE) approach [8–14]. MASK, the new ARIA initia-
tive, focusses on: (1) the implementation of multi-secto-
ral care pathways; (2) deploying emerging technologies; 
(3) with real world data; (4) to provide individualized 
and predictive medicine; (5) in patients with rhinitis and 
asthma multi-morbidity; (6) to be used by a multi-disci-
plinary group or by patients themselves (self-care) using 
the AIRWAYS ICPs algorithm (Fig. 1); (7) across the life 
cycle [15, 16].
An App (Android and iOS) [16] has been developed 
and is associated with an inter-operable tablet for physi-
cians and other healthcare professionals (HCPs) [17]. An 
elegant and simple common language, the Visual Ana-
logue Scale (VAS), is used to assess and manage AR [18, 
19]. It is currently being combined with allergen and pol-
lution exposure using various methods including Google 
Trends [20, 21]. MASK also includes EQ-5D [22, 23] and 
CARAT.
The European Commission is co-funding a large col-
laborative project named JA-CHRODIS (Joint Action on 
Chronic Diseases and Promoting Healthy Ageing across 
the Life Cycle) in the context of the 2nd EU Health Pro-
gramme 2008–2013 [24]. JA-CHRODIS has developed a 
check-list of 28 items for the evaluation of Good Prac-
tices (GP) (http://chrodis.eu/our-work/04-knowledge-
platform/). According to the JA-CHRODIS “A GP is 
not only a practice that is good, but a practice that has 
been proven to work well and produce good results, and 
is therefore recommended as a model. It is a successful 
experience, which has been tested and validated, in the 
broad sense, which has been repeated and deserves to 
be shared so that a greater number of people can adopt 
it.” (http://www.fao.org/docrep/017/ap784e/ap784e.pdf; 
http://eurohealthnet.eu/sites/eurohealthnet.eu/files/
CHRODIS_Promotion%20Material%20WP5-08.pdf).
Aim of the present paper
MASK is one of the GPs of SUNFRAIL (Reference Sites 
Network for Prevention and Care of Frailty and Chronic 
Conditions in community dwelling persons of EU Coun-
tries, www.sunfrail.eu), an EU project which evaluates 
GPs on chronic diseases. The aim of the present paper is 
to report the results of evaluation performed by using the 
JA-CHRODIS check-list on MASK. The paper has been 
devised and written by an expert group including MASK 
and SUNFRAIL experts.
CHRODIS check list
 1. Equity
(a) Design 
Box 1: In design, relevant dimensions of equity are adequately taken 
into consideration and are targeted (i.e. gender, socioeconomic 
status, ethnicity, rural–urban area, vulnerable groups)
People with low socioeconomic status bear a dispropor-
tionate burden of allergic diseases. The MASK Action 
Plan was devised by a group of 450 members. Activities 
are proposed in a logical framework ranging from exist-
ing tools to novel information communication technol-
ogy (ICT) tools and innovative health systems in order to 
provide an integrated solution for AR and asthma multi-
morbidity across the life cycle. The model of MASK 
can then be adapted for the health promotion of AHA 
and management of CRDs across the lifecycle [25]. All 
dimensions of equity are considered in MASK:
  • AR and asthma are life-long diseases often starting 
early in life. Regional organisations engaged in the 
EIP on AHA and holding Reference Site status as a 
result of the 2016 call obtained a grant to facilitate 
the transfer of innovative practices (Twinning) for 
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implementation in other regions (http://www.scale-
aha.eu/news.html). MASK is involved in a Twinning 
of 24 Reference Sites to better understand and man-
age AR and asthma in old age adults [26].
  • There are gender differences across the lifecycle.
  • There are urban and rural differences (users of the 
App are geolocalized).
  • Different socio-economic statuses are assessed in the 
Twinning.
  • The action plan envisions the use of ICT as enablers 
to address the inequality of allergic diseases on per-
sons with low socioeconomic status by making the 
tool freely available to all.
Moreover, MASK proposes a common framework of 
integrated care pathways (ICPs) to facilitate compara-
bility and trans-national initiatives targeted to all popu-
lations according to culture, health systems and income 
[27].
(b) Implementation 
AIRWAYS ICPs has developed a strategy for low-
resource settings based on existing WHO initiatives such 
as the WHO Package of Essential Non-communicable 
disease (PEN [28]) or validated primary management 
strategies in low- and middle-income countries (LMICs) 
[29]. The first ARIA workshop report (1999) already had 
a specific goal to reach patients in LMICs [6]. The exper-
tise of GARD for the deployment of GPs in LMICs is 
used to address the equity dimensions of MASK. Gender 
is also considered in ARIA.
2. Practice
(a) Comprehensiveness of the intervention 
Pharmacist
Specialist
(asthma
Self-management
Improvement
Failure
Improvement
Failure
Treatment
Incorrect
diagnosis
Severity
Incorrect
diagnosis
Severity
Primary care
allergic rhinitis symptoms
OTC
medicaon
Check For
asthma 
YES
Fig. 1 Care pathways for rhinitis (from Bousquet et al. [2, 3])
Box 2: In implementation, specific actions are taken to address the 
equity dimensions
Box 3: The intervention has a comprehensive approach to health 
promotion addressing all relevant determinants (e.g. social determi‑
nants) and using different strategies (e.g. setting approach)
Health promotion is an essential component of GARD 
and MASK. It is extremely important in AR, particularly 
for the avoidance of allergen, indoor and outdoor air pol-
lution. Google Trends results will be included next year 
to inform users of the pollen season. A research project 
using the App has been initiated to determine the impact 
of air pollution in AR (POLLAR). Patient empowerment 
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is an essential component of MASK and follows the con-
clusions of the EU Council of the Polish Presidency [30, 
31]. Social determinants are considered in the Twinning 
[26].
WHO defines a setting as “the place or social con-
text in which people engage in daily activities in which 
environmental, organizational, and personal factors 
interact to affect health and wellbeing” [32]. The goal of 
the settings approach is to create supportive environ-
ments for optimal health [33]. The model’s key principles 
include flexibility, community participation, partnership, 
empowerment and equity [32]. One aspect of the current 
settings approaches of MASK is to improve work and 
school productivity [34]. Schools have long been used 
as a setting to provide health services and, in the future, 
improvement of school performance and exams may be 
achievable.
The practice implements (1) multi-sectoral care path-
ways (2) using emerging technologies (3) with real world 
data (4) for individualized and predictive medicine (5) in 
rhinitis and asthma multimorbidity, (6) by a multi-disci-
plinary group or by patients themselves (self-care) using 
the AIRWAYS ICPs algorithm (7) across the life cycle [16, 
47].
The practice is built on the 19-year scientific basis and 
experience of stakeholders of the ARIA Working Group 
[2, 3, 6, 7, 15, 16, 36, 37, 48–53]. Guidelines supporting 
MASK are based on the GRADE approach and have been 
developed at McMaster University [8–14, 54].
MASK was initiated by the WHO Collaborating Centre 
for Asthma and Rhinitis in 2011 and the pilot phase has 
been completed [8, 12, 13, 17, 36, 55]. MASK proposes to 
study the symptoms (rhinitis, conjunctivitis and asthma) 
and work productivity of patients suffering from allergic 
symptoms, in particular during the pollen season. Geolo-
calized users assess their daily symptom control using the 
touchscreen functionality on their smart phone to click 
on 5 consecutive VAS measures (VAS-global, VAS-nasal, 
VAS-ocular, VAS-asthma and VAS-work) and type(s) of 
treatment used.
A clinical decision support system has been  finalized 
based on an ARIA consensus report [47] and digitalized 
on tablets for HCPs [17]. A care pathway from the patient 
to the health care professional has been built. It is cur-
rently being combined with Google Trends to assess pol-
len seasons [20, 21], pollen levels and pollution data.
The application is freely available in 17 languages 
from the Apple App store (iOS) and Google Play Store 
(Android) in 22 countries (translated and back-trans-
lated, culturally adapted and legally compliant). Due to 
the simplicity of the tool, it can be used in developed and 
many developing countries (if a smart phone is available).
A pilot study in 5000 users across 20 countries has 
been analysed. A simple questionnaire administered by 
cell phones has enabled the identification of phenotypic 
differences between a priori defined rhinitis groups. 
The results of the study suggested novel concepts and 
research questions in AR that cannot be identified using 
classical methods [56]. A cross-sectional study evalu-
ated the impact of uncontrolled rhinitis assessed by VAS 
on work productivity using cell phone data collection. It 
also compared the impact of asthma, rhinitis and con-
junctivitis on work [34]. In users with uncontrolled rhi-
nitis, approximately 90% had some work impairment and 
over 50% had severe work impairment. This pilot study 
provided not only proof-of-concept for data on the work 
impairment collected with the app but also data on the 
app itself, especially the distribution of responses for 
the VAS. This supports the interpretation that persons 
with rhinitis report both the presence and the absence 
Box 4: An effective partnership is in place (e.g. multidisciplinary, inter‑
sector, multi‑/and alliances)
MASK activities are being implemented by a group of 
450 members in 70 countries. All stakeholders needed for 
the implementation of an action plan at the national and 
local levels actively participate. ARIA has a specific mod-
ule for pharmacists [35]. Members also include those of 
previous initiatives such as ARIA [36] and GARD [4, 37]. 
The majority of members have been working together 
since 1999. The  GA2LEN (Global Allergy and Asthma 
European Network, FP6) network of excellence centres of 
allergy and asthma [38], EUFOREA (European Forum for 
Research and Education in Allergy and Airway Diseases) 
[39, 40] and members of EIP on AHA commitments for 
action are also involved. Scientific societies participate in 
the project as well.
Box 5: The intervention is aligned with a policy plan at local, national, 
institutional and international levels
The intervention is linked with WHO (GARD research 
demonstration project), the EU (DG Research [41–43], 
DG CONNECT and DG Santé [44]), National Plans (e.g. 
Finnish Allergy Plan) [45, 46] and EIP on AHA Reference 
Sites. ARIA is used by the European Medicines Agency 
(EMA) and the Australian Medical Agency for the label-
ling of AR interventions.
(b) Description of the practice 
Box 6: The design is appropriate and built upon relevant data, theory, 
context, evidence and previous practice including pilot studies
Page 5 of 16Bousquet et al. Clin Transl Allergy  (2017) 7:37 
of symptoms (submitted). The results of the treatments 
reported by users may represent a breakthrough in the 
management of CRDs (in preparation).
Aiding risk stratification in chronic disease patients 
with a common strategy, AIRWAYS ICPs has developed 
a simple stratification algorithm for asthma control and 
severity (following a 2009 WHO meeting) which can 
be extended to all chronic diseases unifying the classi-
fication of the diseases for clinical, research and public 
health use [49, 57, 58].
The potential for inequities arising from the use of MASK 
has been considered. MASK might raise legal and ethical 
questions in employment (work productivity) or access to 
private insurance. However, users are anonymized. The 
freely-available App increases accessibility for vulnerable 
groups, although concerns on the digital divide should be 
addressed [59]. The application requires a smart phone, 
which limits its universal access at the moment. Not-
withstanding, the authors consider that  the information 
obtained from the current smart phone users will benefit 
future users, in a progressively higher number.
Box 7: The design describes the practice in terms of purpose, SMART 
objectives, methods (e.g. recruitment, location of intervention, con‑
crete activities), and timeframe (sequence, frequency and duration)
The MASK approach is following SMART objectives:
  • Specific—Target a specific area for improvement (AR 
and multi-morbid asthma, addressing symptoms, 
medication and quality of life).
  • Measurable—Quantify an indicator of progress (EQ-
5D, VAS measures, work productivity).
  • Agreed upon—Healthcare professionals, policy mak-
ers and patients.
  • Realistic—Objectives are achievable. Results are 
already obtained for the pilot study, given available 
resources. There are over 11,000 users.
  • Time-related—Results are available and a plan with 
objectives fixed for 2017 and 2018 is in place.
The methods are clearly stated and published [16].
  • Recruitment: The Allergy Diary was used by people 
who downloaded it from the Apple App store, Google 
Play store, and other Internet sources. A few users were 
clinic patients that were asked by their physicians to 
access the app. Due to anonymization (i.e. no name or 
address) of data, no personal identifiers were gathered. 
None of the users were enrolled in a clinical study as 
we aimed to have a real life assessment. There was no 
specific advertisement or other recruitment campaign.
  • The Allergy Diary collects information on allergic 
symptoms.
 
3. Ethical considerations 
Box 8: The intervention is implemented equitably, i.e. proportional to 
needs
Box 9: Potential burdens, including harm, of the intervention for the 
target population are addressed
ICT can improve health outcomes, quality of life and 
efficiency of health care processes but may also contain 
disruptive consequences. Moreover, the implementation 
of ‘e-health applications’ is rather complicated. E-health 
applications do not (often) provide direct benefit that 
can be easily measured [60]. Incentivising further tech-
nological development without putting enough emphasis 
on and properly supporting, even financially, its adop-
tion is likely to widen the serious ‘technology consump-
tion gap’ that we all witness [61]. Nevertheless, mobile 
phones are widely used among populations with poor 
access to health care and limited education. They provide 
the opportunity to disseminate relevant information and 
empower individuals for guided self management of dis-
eases. MASK is currently investigating these aspects.
Box 10: The intervention’s objectives and strategy are transparent to 
the target population and stakeholders involved
The Terms of Use [56] have been translated into all 
relevant languages and customized according to the leg-
islation of each country in order to allow the use of the 
results for research purposes.
The data were anonymized except for geolocalized data 
to the area-level [56]. The European Commission’s Arti-
cle 29 Working Party states that geolocation information 
is personal data (http://ec.europa.eu/newsroom/just/
item-detail.cfm?item_id=50083) and that information 
can be collected, shared, or stored only with the express 
consent of the individual. This is the case for MASK 
because users agree to geolocation in the terms of use of 
the App. Moreover, geolocation is optional and each user 
can allow it or not on his/her cell phone. Geolocation, if 
active, can be disallowed at any time. Finally, geolocation 
is not used in the data mining process and the phone IP is 
not retained.
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Formal Institutional Review Board (IRB) approval was 
not required for the first two studies. An IRB approval 
has been requested for the Twinning. Although reg-
istered as CE1, the App is considered as a non-medical 
device by the MHRA (Medicines and Healthcare prod-
ucts Regulatory Agency, UK Government, www.gov.uk/
government/organisations/medicines-and-healthcare-
products-regulatory-agency) and by the Ethics Commit-
tee of Cologne University.
4. Evaluation 
However, a sufficient amount of data is needed and 
results are expected in 2018.
Box 11: There is a defined and appropriate evaluation framework 
assessing structure, process and outcomes. The use of validated 
tools and/or the results of evaluation are linked to actions to 
reshape the implementation accordingly and/or the intervention is 
assessed for efficiency (cost vs. outcome)
MASK data are available using a real-time database 
and results are regularly published. Some 2016 data are 
already in press [34, 56].
The results of 2016 have induced a change in some of 
the questions of the App and in the re-analysis of data 
using a novel approach, which suits observational studies 
better. In randomized controlled trials (RCTs), each sub-
ject is randomly assigned to a treated or control group, 
whereas observational studies examine the possible effect 
of a treatment on subjects where the investigator has 
no control over the experiment and cannot randomize 
the allocation of subjects [62]. This can create bias, may 
mask cause and effect relationships or, alternatively, sug-
gest incorrect correlations. However, observational stud-
ies reflect “real world” use and practice more closely than 
RCTs in terms of the heterogeneous patient populations 
included and the variety of medical interventions [63]. 
They can provide clinically-relevant information, not 
necessarily provided by RCTs. Given the limitations of 
an observational study approach, it is important to opti-
mize their study design to maximize their validity. In par-
ticular, known causes of bias and confounding should be 
measured [63].
The Twinning questionnaire in the 24 Reference Sites 
has been updated based on 2016 data [26].
One of the major goals of MASK is to improve loss 
of work productivity due to AR. Costs range from 30 to 
60 B€ a year in Europe [64]. The pilot study allowed us to 
show that MASK can accurately assess work productivity 
[34]. In the Twinning, work productivity will be assessed 
in several settings including the Northern Ireland NHS, 
North of England and Valencienne, France hospitals.
EQ-5D is one of the MASK tools and will make it pos-
sible to assess the cost-effectiveness of interventions. 
Box 12: Evaluation results achieve the stated goals and objectives
The results of ARIA are clear, but the results of MASK 
can only be assessed and its impact understood when a 
sufficient number of users will have been monitored. 
Interim data from pilot studies are encouraging [26, 34, 
56]. They show in 11,300 users (June 17) that the phe-
notype of AR can be assessed and some features such as 
work productivity can be appraised.
Box 13: Evaluation Information/monitoring systems are in place to 
regularly deliver data aligned with evaluation and reporting needs
A real-time database is available and the statistical 
analysis of the data is in place, allowing for a few prelimi-
nary reports to be published or in preparation already.
Box 14: The intervention is assessed for outcomes, intended or 
unintended
Outcomes measured by MASK include not only mul-
tiple symptoms but also EQ-5D and work productivity 
assessment.
5. Empowerment and participation 
Box 15: The intervention develops strengths, resources and autonomy 
in the target population(s) (e.g. assets‑based, salotogenic approach)
MASK focusses on factors that support human health and 
well-being, rather than on factors that cause disease. This 
“salotogenic approach” is concerned with the relationship 
between health, stress, and coping [65]. AR is particularly 
suited for the model since AR is not a lethal disease, does 
not lead to ED visits or hospitalizations but has a major 
impact on quality-of-life [66, 67], school and work [34, 
68–78]. The evolutionary nature of the development of 
the app allows for continual assessment of both recording 
and intervention. This offers the potential for the techno-
logical intervention, always blended with clinician input, 
to induce behavioural change in patients to improve 
their outcomes [79]. Furthermore, MASK may provide a 
model for evaluating feasibility and effectiveness of using 
mobile technology for empowering individuals for diag-
nosis, early recognition of worsening of their diseases and 
guided self management of chronic diseases.
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Box 16: The intervention achieves meaningful participation among 
the intended target population
Patients, clinicians and other HCPs are confronted with 
various treatment choices for the management of AR. 
This contributes to considerable variation in clinical 
practice and patients are often unsatisfied by their treat-
ment. Severe Chronic Upper Airway Disease (SCUAD) 
defines uncontrolled AR patients despite optimal phar-
macotherapy [80] and accounts for 10–20% of patients 
receiving treatment for AR [81]. A large number of AR 
patients appear to be self-managing their condition with 
few interactions with their doctor regarding their allergy 
prescription [82]. Many AR patients use over-the-coun-
ter (OTC) drugs [35, 83, 84] and only a fraction have 
had a medical consultation. The vast majority of patients 
who visit GPs or specialists have moderate/severe rhini-
tis [85–87]. A large number of OTC or prescribed drugs 
are available for the patient who can also choose alterna-
tive medicine or allergen-specific immunotherapy [88]. 
The app will also be useful in  the early identification of 
those who are unaware of being affected by allergic rhi-
nitis, and  of the fact that symptoms can be controlled. 
The MASK ICPs consider a multi-disciplinary approach 
including self-management as proposed by AIRWAYS 
ICPs [2]. In the Allergy Diary, both OTC and prescribed 
medications are listed and the list has been customized 
for each country.
In order to assess the participation of the target popu-
lation, a qualitative study has been carried out in users in 
France (MADoPA, http://www.madopa.fr/). The results 
of the study are under evaluation and we plan to extend 
the study to the European population to better under-
stand the participation of the target population. The 
preliminary data of the study indicated that users were 
willing to show their data to their physician. A new func-
tionality has therefore been added (March 1, 2017) allow-
ing patients to print their data. There is no direct link 
from the patient’s cell phone to the physician’s computer 
(to comply with regulations).
Box 17: The intervention is designed and implemented in consulta‑
tion with the target population
Quality of life—normal life despite the disease, cure 
and prevention—represents the patient’s goal in AR 
and asthma [31]. Patient perspective, represented by 
patients’  organizations, arises from the collective expe-
rience of patients (as well as their parents and partners) 
living with allergy. The European Federation of Allergy 
and Airways Diseases Patients’ Associations (EFA, http://
www.efanet) is an alliance of 41 allergy, asthma and 
chronic obstructive pulmonary disease (COPD) patients’ 
organizations in 25 countries. Patient perspective has 
been incorporated at all levels of ARIA, GARD and 
MASK, from the early steps.
The goal and rationale of patient involvement in medi-
cal decisions is patient empowerment [31]. Empowered 
patients know their disease, have the skills and motiva-
tion to take good care in their everyday life, adjust treat-
ment, are prepared in new or potentially exacerbating 
situations, detect side-effects, contact a healthcare pro-
fessional when needed and adhere to treatment regime. 
Many tools support empowerment, shared decision mak-
ing models and patient education. Another key aspect of 
patient involvement in medical decisions is the involve-
ment of patient representatives in the healthcare policy 
and organization in practice. The members of EFA have 
developed tools to help in involvement in medical deci-
sions and empowerment. These tools were acknowledged 
while developing MASK.
6. Target population 
Box 18: Target populations are defined on the basis of needs assess‑
ment including strengths and other characteristics
Box 19: The engagement of intermediaries/multipliers is used to 
promote the meaningful participation of the target population
A transfer innovation is ongoing from the App devel-
oped by the MACVIA-France EIP on AHA reference site 
(Allergy Diary) to 25 Reference Sites or regions across 
Europe. Validated ICT tools (Allergy Diary and CARAT: 
Control of Allergic Rhinitis and Asthma Test) are being 
used [26].
7. Sustainability 
Box 20: The continuation of the intervention is ensured through insti‑
tutional ownership that guarantees funding and human resources
MASK belongs to the Fondation Partenariale FMC VIA 
LR of the French Ministry of Education and Research 
(Fondation des maladies chroniques et du vieillissement 
actif—Languedoc-Roussillon, NOR: MENS1500573A, 
arrêté du 9-9-2015, MENESR—DGESIP B1-3). The four 
partners of the Foundation are the University of Mont-
pellier, the Région Occitanie, and the University hospitals 
of Montpellier and Nîmes. There is a guarantee for the 
funding and human resources needed to accomplish the 
project.
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However it should be noted that sustained engagement 
by individual patients is not necessarily a measure of suc-
cess. For example, patients with intermittent allergic rhi-
nitis may choose to inform MASK only at specific times 
of the year.
MACVIA-France Reference Site [89] and to lead the 
MASK project (see Box 20).
9. Scalability 
Box 21: There is broad support for the intervention amongst those 
who implement it
There are  450 stakeholders in the MASK working 
groups, from over 70 countries and all continents. They 
represent all groups from patients to policy makers, prac-
ticing health care professionals and key opinion leaders.
Box 22: There is broad support for the intervention amongst the 
intended target populations
This has not yet been evaluated. It is planned for 2017 
by the Twinning [26].
8. Governance 
Box 23: The intervention includes an adequate estimation of the 
human resources, material and budget requirements in clear rela‑
tion with committed tasks
See above (Box 20). Initial seed funding has been donated 
from private partners (Unrestricted educational grant) 
as well as from EU Structural and Development Funds. 
The private sector donors did not participate in any 
decision on the project. Funding for 2018  is secured. 
A business plan has been set up by the SME (small and 
medium  enterprise) Kyomed (Montpellier) and by 
EUFOREA (Belgian ASBL).
Box 24: Sources of funding are specified in regards to stability and 
commitment
See Box 23.
Box 25: Organisational structures are clearly defined and described 
(i.e. responsibility assignments, flows of communication and 
work  as well as accountabilities)
These were the first steps of the MASK project. The 
Fondation Partenariale “Fondation des maladies chro-
niques et du vieillissement actif—Languedoc-Roussil-
lon” was established to coordinate the actions of the 
Box 26: Potential impact on the population targeted (if scaled up) is 
assessed
MASK focuses on factors that support human health 
and well-being, as well as on factors that cause disease 
(“salutogenic approach” [65]). An important outcome of 
MASK is work productivity. The same applies for school 
learning as AR has a detrimental effect on learning and 
on  the results of exams [90]. Quality-of-life is tested 
using EQ-5D.
One major problem of all allergic diseases is compli-
ance with treatment. If  appropriately theorized and 
developed, ICT solutions are expected to improve com-
pliance possibly by inducing behavioural change, and 
therefore the control of AR and asthma [91]. However, 
this component has not yet been tested in MASK.
Box 27: There is a specific knowledge transfer strategy in place (evi‑
dence into practice)
The scaling up strategy uses the recommendations 
of the European Innovation Partnership on Active and 
Healthy Ageing [51]. The overarching goals of the MASK 
approach are to provide an active and healthy life to rhi-
nitis sufferers, whatever their age, sex or socio-economic 
status, in order to reduce health and social inequalities 
incurred by the disease.
Scaling-up strategies in Europe and beyond The scal-
ing up strategy has been clearly defined and approved by 
AIRWAYS ICPs members. It follows the EIP-AHA rec-
ommendations on a 5-step framework: [1] what to scale 
up: (1–1) databases of Good Practices, (1–2) assessment 
of viability of the scaling up of Good Practices, (1–3) 
classification of Good Practices for local replication; and 
[2] how to scale up: (2–1) facilitating partnerships for 
scaling up, (2–2) implementation of key success factors 
and lessons learnt, including emerging technologies for 
individualised and predictive medicine. Scaling-up will 
take place within and beyond Europe with GARD [25, 30, 
31, 45, 92].
MASK is implemented in 22 countries (17 languages). 
We aim to include five more countries in 2017.
Strengthening the WHO NCD Action Plan AIRWAYS 
ICPs is a GARD demonstration project (WH0). It is 
in line with the WHO NCD Action Plan since it aims 
to reduce the preventable and avoidable burden of 
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morbidity, mortality and disability by means of multi-sec-
toral collaboration and cooperation at national, regional 
and global levels.
checklist. However, one ear, nose and throat (ENT) 
expert from Belgium and one Allergy-Public health 
expert from the UK found that many items were not 
partly or not in line with the checklist. Overall, from 75 
to 94% of items were found to be in line with the CHRO-
DIS checklist.
Comments are provided for a percentage of agreement 
< 75%.
Box  2 At this stage there is no change in MASK 
incurred by the SurveyMonkey. There will be a revision 
of the product at the end of 2017 taking the comments 
into consideration.
Box 8 Since the SurveyMonkey, ethical committee has 
been granted (Kohln-Bohn Region) and the MHRA and 
the ethics committee have indicated that the App is not a 
medical device.
Box  12 More data have been evaluated and there is a 
strong consistency of results.
Box  13 At this stage there is no change in MASK 
incurred by the SurveyMonkey. There will be a revision 
of the product at the end of 2017 taking the comments 
into consideration.
Box  17 At this stage there is no change in MASK 
incurred by the SurveyMonkey. There will be a revision 
of the product at the end of 2017 taking the comments 
into consideration.
Box  18 At this stage there is no change in MASK 
incurred by the SurveyMonkey. There will be a revision 
of the product at the end of 2017 taking the comments 
into consideration.
Fig. 2 Results of the SurveyMonkey
Box 28: An analysis of requirements for eventual scaling up such 
as foreseen barriers and facilitators (e.g. resources, organisational 
commitment, etc.) is available
We use the expertise of WHO GARD to overcome 
generic barriers that may impact scaling up. Moreover, in 
each country, a MASK working group is in place to over-
come local barriers.
10. Assessment of the criteria using SurveyMonkey
A SurveyMonkey questionnaire is the easiest way to 
create surveys and to obtain answers. It allows a survey to 
be prepared quickly and targeted answers to be obtained 
from the audience requested. We conducted a Survey-
Monkey (www.surveymonkey.com) of expert clinical 
opinion on the 28 items to assess the robustness of the 
answers to the boxes. The SurveyMonkey was sent to 34 
experts from different fields. For each item, respondents 
indicated their level of agreement on a VAS ranging from 
0 (strongly disagree) to 100 (strongly agree). 18 experts 
from 12 countries responded (53%). It was decided 
pre-hoc to stop the survey when a 50% response was 
achieved. Respondents included allergists, general practi-
tioners, pharmacologists, respiratory physicians or Public 
Health professionals. Two of the experts did not disclose 
their affiliation. Five SUNFRAIL experts were included in 
the survey. We categorized a priori the level of response 
(in line with the checklist ≥  80, partly in line with the 
checklist: 50–79 and not in line with the checklist < 50).
The results are presented in Fig.  2. Most experts 
agreed that most items were in line with the CHRODIS 
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Box  19 The transfer of innovation is increasing. It is 
already implemented in Australia, Brazil, Mexico, and 
is in process in Argentina, Paraguay and Uruguay. Novel 
approaches including air pollution and allergen exposure 
are being considered and should be available by the end 
of 2018.
Box  20 New private funding has been secured. More-
over, the continuation of the intervention is ensured 
through institutional ownership.
Box  22 At this stage there is no change in MASK 
incurred by the SurveyMonkey. There will be a revision 
of the product at the end of 2017 taking the comments 
into consideration.
Box 23 See Box 20.
Box 24 See Box 20.
Box  25 At this stage there is no change in MASK 
incurred by the SurveyMonkey.
Box  27 At this stage there is no change in MASK 
incurred by the SurveyMonkey.
Box  28 At this stage there is no change in MASK 
incurred by the SurveyMonkey. There will be a revision 
of the product at the end of 2017 taking the comments 
into consideration.
Conclusions
MASK assessment using The European Union Joint 
Action JA-CHRODIS (Joint Action on Chronic Diseases 
and Promoting Healthy Ageing across the Life Cycle) 
checklist of 28 items for the evaluation of Good Practices 
by a panel of experts from several countries indicates 
that it is in line with the CHRODIS recommendations.
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Appendix 1: Terms of use for the UK
By installing and using this app, you agree to the appli-
cability of these Terms of Use (and to the privacy policy 
below). If you do not agree to these Terms of Use, you 
must not download or use this app, copyright of which is 
protected.
 1. This app provides a digital way for you to keep a 
diary with respect to the symptoms of an allergy. The 
diary gives you insight into your allergies by enabling 
you to ‘score’ your allergy-related symptoms and 
view your results in a graph. An advice text is shown 
together with the results and you may be advised to 
see a healthcare provider.
 2. This app is intended for general information pur-
poses and must not be used as a substitute for any 
kind of professional and/or medical advice.
 3. This “Allergy diary App by MACVIA-ARIA” is based 
on previous recommendations and the  ARIA® guide-
lines (2015) with permission of  ARIA®. Its diagnostic 
and therapeutic uses should be carried out in con-
junction with patients’ physicians. The  ARIA® guide-
lines have been published in the peer-reviewed med-
ical literature and have been reviewed and approved 
by medical experts worldwide. The use of this appli-
cation in all countries should be carried out only 
with the specific therapies that are licensed in that 
country. MACVIA and ARIA will be held harmless 
for any inappropriate use of this application. Users of 
the application should read, understand and follow 
the approved prescribing information for any medi-
cations used in conjunction with the application.
 4. This app is provided to you for your personal use and 
you must not use it to process the personal informa-
tion of any other person.
 5. This app, and the information contained in it, is 
provided to you “as is,” for informational purposes 
only, with no guarantee of completeness, accuracy, 
timeliness or of the results obtained from the use of 
this information, and without warranty of any kind, 
express or implied, including but not limited to war-
ranties of performance, merchantability and fitness 
for a particular purpose.
 6. You recognise that the app functionality may be 
affected by changes in the operating system of your 
device. It is your responsibility to check for updates 
in order to determine if you have the most current 
version of the app, to ensure that it is working prop-
erly.
 7. Neither Peercode or MACVIA-ARIA, nor its subsid-
iaries, affiliates and/or respective employees or man-
agement, is liable for any damages, including, and 
without limitation, direct, indirect, consequential or 
incidental damages resulting from or in connection 
with any information, materials, qualifications or 
recommendations related to this app.
 8. Peercode/MACVIA-ARIA is not liable for any 
damages resulting from the use (or inability to use) 
this app, including damages caused by viruses or 
any incorrectness or incompleteness of the Infor-
mation. Peercode/MACVIA-ARIA is also not liable 
for damages resulting from the use of electronic 
devices for communication with this app, includ-
ing—but not limited to—damages resulting from 
failure or delay in delivery of electronic messages, 
interception or manipulation of electronic mes-
sages by third parties or by software/hardware used 
for electronic communications and transmission of 
viruses.
 9. If this app directly or indirectly provides links to 
other information, such as information on web-
sites maintained by third parties over whom Peer-
code/MACVIA-ARIA has no control, Peercode/
MACVIA-ARIA is not liable for the use or content 
of this information.
 10. Peercode/MACVIA-ARIA reserves the right to 
change the Allergy Diary App Terms of Use at any 
time and without notice.
 11. These Terms of Use shall be governed by and con-
strued in accordance with the laws of the Nether-
lands. The competent court in Amsterdam shall 
settle all disputes arising in connection with these 
terms.
Contact information
Peercode may be contacted via:
Address: Oudenhof 4, 4191 NW Geldermalsen,
Country: The Netherlands
Phone: +31 (0)88 0084100
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